Trial Profile

A Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir in Renally-Impaired Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection (EXPEDITION-5)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 25 Jul 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

13 Nov 2018 Results assessing the efficacy and safety of Glecaprevir/Pibrentasvir in patients with HCV genotype GT 1-6 infection and severe renal impairment using data from EXPEDITION-4 and EXPEDITION-5 studies (n=205), presented at The Liver Meeting 2018: 69th Annual Meeting of the American Association for the Study of Liver Diseases
14 Jun 2018 Status changed from active, no longer recruiting to completed.
05 Jun 2018 Preliminary results presented at the Digestive Disease Week 2018

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com